hero image

Biogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016

December 21, 2015 Investor Relations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year end 2015 financial results on Wednesday, January 27, 2016, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:30 am EST. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL, for one month.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.

 

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

thumb
October 6, 2021
Biogen to Report Third Quarter 2021 Financial Results October 20, 2021

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report third quarter 2021 financial results Wednesday, October 20, 2021, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

thumb
October 4, 2021
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress

Improvement achieved in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical program Sage to host conference call on October 4, 2021 at 8:00am ET